Evidence map›Paper›PMID 40930122›Full record

ReviewRenal failure2025

Histone methylation of kidney disease: fact or fantasy?

Lan Hu, Hua Jin, Xu Li, Qin Hu, Xuelian Zhang

Abstract readReview
In one paragraph

Review in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lan HuFirst School of Clinical Medicine, Anhui University of Chinese Medicine, Hefei, China.
Hua JinFirst School of Clinical Medicine, Anhui University of Chinese Medicine, Hefei, China.
Xu LiFirst School of Clinical Medicine, Anhui University of Chinese Medicine, Hefei, China.
Qin HuFirst School of Clinical Medicine, Anhui University of Chinese Medicine, Hefei, China.
Xuelian ZhangDepartment of Nephrology, The First Affiliated Hospital, Anhui University of Chinese Medicine, Hefei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histone methylation (HMT), the enzymatic addition of methyl groups to specific histone residues by histone methyltransferases, constitutes a key regulatory mechanism in gene expression and post-translational modulation. Although studies have explored HMT's role in oncogenesis and other organ-specific disorders, HMT is now implicated in the pathogenesis of kidney diseases. A broad spectrum of experimental models, including both

Indexed as

Histone-Lysine N-MethyltransferaseHistonesKidney DiseasesAnimalsHumansKidneyMethylationHistone-Lysine N-MethyltransferaseHistonesEpigeneticshistone methylationkidney diseasesmethyltransferase

Identifiers

PMID40930122
PMCPMC12424148

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.